Applied Clinical Trials
Only eight percent of CNS drugs will reach approval, in part because of the high adverse effects standards.
Pierre Geoffroy
Advertisement
Articles by Pierre Geoffroy
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ICON Selects Microsoft as Preferred Technology Partner to Scale Agentic AI Platform Across Clinical Trial Lifecycle
2
ACT Brief: Mixed FSP Strategy, DIA Meeting Trends, and Patient Voice in Oncology
3
ACT Brief: Real-Time Evidence Generation, Protocol Digitization, and Decentralized Trial Flexibility
4
2026 DIA Global Annual Meeting: Where Mixed Models Create the Most Value—and What It Takes to Make Them Work
5